Nabla, a leading AI assistant widely used in clinical care, has announced a new leadership appointment. Dr. Matt Sakumoto joins the company as Chief Clinical Product Officer. His arrival marks a key step in Nabla’s growth, especially as the company expands its clinician-led approach to developing AI tools grounded in real-world healthcare experience.

Driving Clinical Focus in AI Development

In his new role, Dr. Sakumoto will shape the clinical vision behind Nabla’s product roadmap. His focus is to ensure that the AI assistant remains clinically rigorous, easy to use, and vital across various healthcare workflows. He will also be a key voice in conversations with customers and partners, helping guide the company’s strategic direction with frontline insights.

By leading clinical strategy, Dr. Sakumoto aims to help Nabla create AI solutions that truly meet the needs of healthcare providers. His expertise will help keep the product aligned with real-world clinical practices and ensure that the technology supports, rather than complicates, patient care.

Enhancing Healthcare Innovation and Leadership

This appointment highlights Nabla’s commitment to expanding its clinical leadership team. With both a Chief Medical Officer and now a Chief Clinical Product Officer, the company emphasizes the importance of clinician input in shaping healthcare AI. This approach underscores Nabla’s belief that effective AI tools must be built by clinicians, for clinicians.

Dr. Sakumoto brings a wealth of experience from his previous roles at Sutter Health, UCSF, and Teladoc Health. There, he worked on clinical informatics, virtual care, and AI integration in complex health systems. He remains active in shaping healthcare AI policies through involvement with organizations like the American College of Physicians, the Coalition for Health AI, and the American Medical Informatics Association.

His background and ongoing engagement with industry groups position him well to help Nabla develop solutions that are both innovative and practical for everyday clinical use. His leadership is expected to help Nabla deepen its impact across healthcare settings and expand its reach in the AI-assisted care space.

Overall, this move signals Nabla’s focus on building AI tools that are grounded in frontline clinical experience. The company is committed to creating technology that reduces administrative burdens and enhances human connection in healthcare. With Dr. Sakumoto onboard, Nabla is well-positioned to continue its growth and innovation in clinical AI.

Inspired by

• https://ai-techpark.com/nabla-appoints-dr-matt-sakumoto-as-chief-clinical-product-officer/